经皮冠状动脉介入治疗联合依达拉奉治疗ST段抬高型急性心肌梗死再灌注损伤的临床观察

Outcomes of percutaneous coronary intervention combined with edaravone injection in treating ST-segment elevation acute myocardial infarction

目的:观察PCI术联合依达拉奉在ST段抬高型急性心肌梗死治疗中的疗效和临床使用的安全性。方法:A组采用常规PCI术联合依达拉奉治疗;B组仅采用常规PCI术,比较两组治疗后的效果。结果:两组均成功行PCI术,术后血流分级、心肌再灌注情况以及ST段回落率无显著差异(P>0.05);48 h后A组患者血清中MDA含量为(3.16±0.12)mol/L,B组患者血清中MDA含量为(4.38±0.13)mol/L,差异有统计学意义(P<0.05);7 d后A组心功能指标优于B组,A组心肌再梗死率和心律失常率均低于B组,差异有统计学意义(P<0.05)。结论:在治疗急性ST段抬高型心肌梗死中,PCI前后应用依达拉奉,可明显改善患者术后的短期心功能,但其长期效果需要进一步研究证实。

Objective To observe the efficacy and clinical security of percutaneous coronary intervention combined with edaravone injection in treating ST-segment elevation acute myocardial infarction. Methods Group A was treated with conventional percutaneous coronary intervention plus edaravone injection, while group B was treated only with conventional percutaneous coronary intervention. Outcomes were compared between these two groups after the intervention. Results The two groups were successfully operated by percutaneous coronary intervention treatment. Thrombolysis in myocardial infarction,TIMI myocardial perfusion grade and ST-segment recovery after operation had no significant difference. After 48 h treatment, MDA in serum of group A was （3.16 ±0.12）mol/L. Serum MDA content in group B, was （4.38 ±0.13）mol/L. The difference was statistically significant （P 〈 0.05）. In addition, 7 d cardiac function indexes and cardiac arrhythmia rate were lower than those in group B （P 〈 0.05）. Conclusions The combination use of percutaneous coronary intervention and edaravone can effectively improve heart function in patients shortly in the treatment of ST-segment elevation acute myocardial infarction.I-Ihowever, the further studies are still needed to evaluate the long term efficacy.